News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stocktwits Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Anavex Life Sciences has filed definitive proxy materials for its 2026 Annual Meeting, urging stockholders to support its six director nominees. This move follows a leadership change and a board refresh effort, with the company highlighting progress on its lead CNS candidate, blarcamesine, and …
AEVEX Corp (AVEX) reported a significant swing to profitability and substantial debt reduction for the first half of 2026, driven by IPO-fueled growth. Total revenue surged to $418.5 million from $154.4 million in the prior year, leading to a net income of $23.3 million …
Key Points Interested in AEVEX Corp.? Here are five stocks we like better. AEVEX reported strong second-quarter results, with revenue doubling year over year to $201.8 million and net income improving to $6.7 million from a prior-year loss. The company raised 2026 guidance to …
AEVEX Corp. filed its Q2 2026 10-Q report, detailing a proposed acquisition of BlackSea Technologies and highlighting persistent material weaknesses in its internal controls over financial reporting. The filing also updated share counts and confirmed the company's emerging growth status. Risks associated with the …
Acquisition to unite battle‑tested air, surface, and subsea autonomous platforms with scaled domestic manufacturing and a mission‑focused culture aligned to DoW priorities. SOLANA BEACH, Calif., August 12, 2026--(BUSINESS WIRE)--AEVEX Corp. (NYSE: AVEX), a leading U.S. defense technology company specializing in autonomous systems, AI‑enabled mission …
The aerospace and defense stock has recovered over four weeks, but weekly context remains mixed as the 12-week return is still negative.
Anavex Life Sciences Corp. (NASDAQ:AVXL) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $21.33. The company, which is developing blarcamesine for neurological diseases, reported a quarterly loss of $0.06 per share, beating analyst expectations. Institutional investors hold …
Anavex Life Sciences has filed its definitive proxy for the 2026 Annual Meeting and is urging stockholders to vote for its six director nominees. The company's board outlined a plan to advance its oral blarcamesine drug and accused PVG of seeking control with minimal …
Researcher looking through microscope ©Michael J. Ermarth Anavex is asking shareholders to re-elect its six nominees at the September 24 annual meeting as activist investor PVG seeks board control during a leadership transition and a critical period for the company's CNS pipeline. Key Investor …
Anavex Life Sciences has filed definitive proxy materials for its 2026 Annual Meeting, urging stockholders to vote for its six director nominees. The company highlights its refreshed, independent Board, decisive actions to stabilize the company and advance its blarcamesine programs for CNS diseases. Anavex …
Anavex Life Sciences (NASDAQ: AVXL) has announced delays in filing its quarterly reports for the periods ending March 31, 2026, and June 30, 2026. The delay for the June 30 report is attributed to an ongoing Special Committee review related to the termination of …
Chelsey Thomas brings more than two decades of national security, legislative, and federal policy experience to AEVEX. SOLANA BEACH, Calif., August 10, 2026--(BUSINESS WIRE)--AEVEX Corp. (NYSE: AVEX) today announced the appointment of Chelsey Thomas as Vice President of Government Affairs. In her new role, …
This article provides a financial overview of Anavex Life Sciences Corp (AVXL), detailing its market capitalization, profitability margins, and a comparison with competitors AGEN and ZNTL. It highlights AVXL's current financial metrics such as its N/A gross, operating, and net margins, and a Return …
This page provides live stock quotes and charts for AEVEX Corp. Class A (AVEX) on the NYSE. It shows the current stock price, daily change, and offers an interactive chart. The article also mentions the absence of analyst ratings and earnings information for AVEX, …
Anavex Life Sciences Corp. (AVXL) is highlighted as a biotech company with significant potential upside, driven by its lead drug candidate, ANAVEX 2-73, for CNS disorders like Alzheimer's and Rett syndrome. Despite current volatility and developmental-stage financial characteristics, analyst ratings suggest a 509.76% upside …
This article provides financial information for Anavex Life Sciences Corp. (NASDAQ: AVXL), including an overview of its financials, statements, statistics, dividends, earnings, and segment performance. It highlights the company's listing on the Nasdaq Stock Market and references data from ICE Data Services and FactSet.
Anavex Life Sciences Corp. (AVXL) is a biopharmaceutical company focused on developing treatments for neurodegenerative and rare diseases, including Alzheimer's and Parkinson's. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), is in various clinical trials. The company's stock shows significant one-year and five-year declines, but …
Woman looking through microscope ©The U.S. National Archives Anavex Life Sciences (NASDAQ:AVXL) has nominated two new independent directors as part of a broader board refresh ahead of its 2026 Annual Meeting, while outlining its strategy to stabilize leadership, defend against a proxy challenge, and …
Anavex Life Sciences announced plans to refresh its Board of Directors by nominating two new independent directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, to stand for election at the 2026 Annual Meeting. This move is part of the company's strategy to enhance stockholder …
This article identifies three promising penny stocks for August 2026: Anavex Life Sciences (AVXL), Enovix (ENVX), and SES AI (SES). Each company operates in innovative sectors like biopharmaceuticals and advanced battery technology. While all three are pre-profitability and face typical penny stock challenges, they …
This is a preliminary contested proxy statement from Anavex Life Sciences Corp. (AVXL) outlining proposals for its 2026 Annual Meeting of Stockholders. The company is facing a proxy contest from PVG Group, which has nominated six candidates for the board, opposing the Executive Committee's …
Vanguard Capital Management has disclosed a 5.03% beneficial stake in Anavex Life Sciences Corp (NASDAQ: AVXL), according to a recent Schedule 13G SEC filing. This stake amounts to 4,663,459 shares as of June 30, 2026, with Vanguard exercising sole voting power over 608,870 shares …
Anavex Life Sciences reported a preliminary net loss of $5.3 million for Q2 FY2026, or $0.06 per share, and held $127.4 million in cash and cash equivalents, which is expected to fund operations into mid-to-late fiscal 2028. The company is focusing on regulatory engagement …
Anavex Life Sciences reported preliminary financial results for its fiscal second quarter ended March 31, 2026, showing decreased net loss and operating expenses year-over-year. The company is focusing on advancing its lead compound ANAVEX®2-73 (blarcamesine) for early Alzheimer's disease, Rett syndrome, and Fragile X …
This page from TradingView provides financial information for Anavex Life Sciences Corp. (BX:12X1) on the BX Swiss exchange. It includes an overview of financials, statements, statistics, dividends, earnings, and segment performance. The content primarily focuses on navigation and financial data categories rather than a …
Search by ticker symbol or company name and select a result to open its chart.